Robert C Gallo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4214240/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of oral polio vaccine and the incidence of COVID-19 in the world. PLoS ONE, 2022, 17, e0265562.	2.5	17
2	Reflections on Some of the Exceptional Features of HTLV-1 and HTLV-1 Research: A Perspective. Frontiers in Immunology, 2022, 13, 859654.	4.8	0
3	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	1
4	Tampering of Viruses and Bacteria with Host DNA Repair: Implications for Cellular Transformation. Cancers, 2021, 13, 241.	3.7	10
5	Letter to the Editor. Risk Analysis, 2021, 41, 387-388.	2.7	2
6	Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines. Journal of Translational Medicine, 2021, 19, 60.	4.4	6
7	Analysis of DnaK Expression from a Strain of Mycoplasma fermentans in Infected HCT116 Human Colon Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 3885.	4.1	6
8	Viruses and Bacteria Associated with Cancer: An Overview. Viruses, 2021, 13, 1039.	3.3	26
9	Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	69
10	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. Vaccine, 2021, 39, 3879-3891.	3.8	3
11	Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2021366118.	7.1	4
12	Some reflections on HIV/AIDS research after 40 years. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L1057-L1058.	2.9	2
13	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. JAMA Network Open, 2021, 4, e2135044.	5.9	18
14	Emerging of a SARS-CoV-2 viral strain with a deletion in nsp1. Journal of Translational Medicine, 2020, 18, 329.	4.4	71
15	Variability of CD4+ Cell Counts in HIV-1–Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 37-44.	2.1	1
16	Can existing live vaccines prevent COVID-19?. Science, 2020, 368, 1187-1188.	12.6	92
17	Inverse correlation between average monthly high temperatures and COVID-19-related death rates in different geographical areas. Journal of Translational Medicine, 2020, 18, 251.	4.4	29
18	Covidâ€19: Time for a paradigm change. Reviews in Medical Virology, 2020, 30, e2134.	8.3	47

#	Article	IF	CITATIONS
19	Role of Mycoplasma Chaperone DnaK in Cellular Transformation. International Journal of Molecular Sciences, 2020, 21, 1311.	4.1	21
20	Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. Journal of Translational Medicine, 2020, 18, 179.	4.4	784
21	HIV/AIDS Research for the Future. Cell Host and Microbe, 2020, 27, 499-501.	11.0	6
22	40 years of the human T-cell leukemia virus: past, present, and future. F1000Research, 2019, 8, 228.	1.6	60
23	Microenvironment tailors nTreg structure and function. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6298-6307.	7.1	22
24	Proteome analysis of Mycoplasma fermentans cultured under aerobic and anaerobic conditions. Translational Medicine Communications, 2019, 4, .	1.4	4
25	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. Journal of Clinical Investigation, 2019, 129, 1314-1328.	8.2	28
26	Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4453-E4462.	7.1	16
27	Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12005-E12014.	7.1	47
28	Time to eradicate HTLV-1: an open letter to WHO. Lancet, The, 2018, 391, 1893-1894.	13.7	97
29	Characterization of cytopathic factors through genome-wide analysis of the Zika viral proteins in fission yeast. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E376-E385.	7.1	56
30	Patterns of conserved gp120 epitope presentation on attached HIV-1 virions. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9893-E9902.	7.1	12
31	Anti-inflammatory effects of H2S during acute bacterial infection: a review. Journal of Translational Medicine, 2017, 15, 100.	4.4	55
32	Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 2017, 137, 41-48.	4.1	116
33	The Exceptional Oncogenicity of HTLV-1. Frontiers in Microbiology, 2017, 8, 1425.	3.5	62
34	Time to Go Back to the Original Name. Frontiers in Microbiology, 2017, 8, 1800.	3.5	12
35	An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. Vaccine Journal, 2016, 23, 618-627.	3.1	7
36	Screening transplant donors for HTLV-1 and -2. Blood, 2016, 128, 3029-3031.	1.4	41

#	Article	IF	CITATIONS
37	Shock and kill with caution. Science, 2016, 354, 177-178.	12.6	21
38	Extracellular vesicles and viruses: Are they close relatives?. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9155-9161.	7.1	368
39	Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13168-13173.	7.1	26
40	A historical personal perspective on human retroviruses and their infection of <scp>T</scp> cells. Transfusion, 2015, 55, 1-9.	1.6	1
41	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14331-14336.	7.1	58
42	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E992-9.	7.1	117
43	Developing a Successful HIV Vaccine. Journal of Infectious Diseases, 2015, 212, S40-S41.	4.0	4
44	Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9412-9417.	7.1	79
45	Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17. Pathogens and Disease, 2015, 73, ftv062.	2.0	14
46	Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015). Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20150199.	4.0	3
47	Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15614-15621.	7.1	88
48	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology, 2014, 471-473, 81-92.	2.4	21
49	The Global Virus Network's testimony on Ebola to the U.S. Senate. F1000Research, 2014, 3, 307.	1.6	Ο
50	Research and discovery of the first human cancer virus, HTLV-1. Best Practice and Research in Clinical Haematology, 2011, 24, 559-565.	1.7	38
51	Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20476-20481.	7.1	64
52	Rapamycin Reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) against R5 Strains of Human Immunodeficiency Virus Type 1 In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 2489-2496.	3.2	33
53	Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17477-17482.	7.1	77
54	A perspective on human herpes virus 6 (HHV-6). Journal of Clinical Virology, 2006, 37, S3.	3.1	3

#	Article	IF	CITATIONS
55	A reflection on HIV/AIDS research after 25 years. Retrovirology, 2006, 3, 72.	2.0	70
56	HIV: dark and light, then and now. Future Virology, 2006, 1, 1-3.	1.8	0
57	Commentary remarks on "HIV/AIDS in China― Cell Research, 2005, 15, 823-823.	12.0	0
58	History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene, 2005, 24, 5926-5930.	5.9	118
59	Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14807-14812.	7.1	147
60	The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet, The, 2005, 366, 1894-1898.	13.7	48
61	HIV/AIDS research after HAART. Research Initiative, Treatment Action: RITA, 2005, 11, 39-41.	0.1	0
62	HIV-1: A Look Back from 20 Years. DNA and Cell Biology, 2004, 23, 191-192.	1.9	2
63	The Discovery of HIV as the Cause of AIDS. New England Journal of Medicine, 2003, 349, 2283-2285.	27.0	214
64	A journey with T cells, primate/human retroviruses and other persisting human T-cell tropic viruses. Reviews in Clinical and Experimental Hematology, 2003, 7, 329-35.	0.1	0
65	HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9972-9977.	7.1	60
66	Human retroviruses after 20 years: a perspective from the past and prospects for their future control. Immunological Reviews, 2002, 185, 236-265.	6.0	56
67	HIV infection and pathogenesis: what about chemokines?. Journal of Clinical Immunology, 1999, 19, 293-299.	3.8	34
68	Kaposi's Sarcoma: Correction. Science, 1999, 283, 1115-1115.	12.6	0
69	Chemokine Receptors and Chemokines in HIV Infection. Journal of Clinical Immunology, 1998, 18, 243-255.	3.8	31
70	Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease. Nature Medicine, 1998, 4, 428-434.	30.7	58
71	Reply to "Anti-KS activity still a mystery― Nature Medicine, 1998, 4, 748-748.	30.7	2
72	CD4 Promoter Transactivation by Human Herpesvirus 6. Journal of Virology, 1998, 72, 8797-8805.	3.4	40

#	Article	IF	CITATIONS
73	Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Medicine, 1997, 3, 651-658.	30.7	161
74	The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection. Nature Medicine, 1996, 2, 1244-1247.	30.7	524
75	HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Medicine, 1995, 1, 321-329.	30.7	74
76	Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Medicine, 1995, 1, 667-673.	30.7	99
77	Human retroviruses in the second decade: A personal perspective. Nature Medicine, 1995, 1, 753-759.	30.7	34
78	Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature, 1995, 375, 64-68.	27.8	220
79	Kaposi's sarcoma in pregnant women. Nature, 1995, 377, 22-22.	27.8	6
80	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature, 1994, 371, 674-680.	27.8	592
81	Infection of the Central Nervous System by Human Retroviruses. Annals of the New York Academy of Sciences, 1994, 724, 125-132.	3.8	1
82	Human Herpesvirus 7 (HHV-7) Strain JI: Independent Confirmation of HHV-7. Journal of Infectious Diseases, 1992, 166, 690-691.	4.0	74
83	Cytokines and Growth Factors in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. Immunological Reviews, 1992, 127, 147-155.	6.0	148
84	Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. Nature, 1991, 349, 533-535.	27.8	280
85	Sequence analysis of original HIV-1. Nature, 1991, 349, 745-746.	27.8	18
86	Gallo's virus sequence. Nature, 1991, 351, 358-358.	27.8	4
87	and his response. Nature, 1991, 351, 358-358.	27.8	2
88	Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature, 1990, 345, 84-86.	27.8	921
89	Kaposi's sarcoma and AIDS. Nature, 1990, 346, 801-802.	27.8	4
90	Human retroviruses: Cancer and aids. International Journal of Cancer, 1989, 44, 2-5.	5.1	5

#	Article	IF	CITATIONS
91	Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature, 1989, 337, 370-373.	27.8	354
92	Proliferative Tâ€Cell Response to HIV Envelope Glycoprotein in Immunized and Infected Primates and Human Beings. Journal of Medical Primatology, 1989, 18, 363-369.	0.6	5
93	Geographic distribution of HTLV-I and identification of a new high-risk population. International Journal of Cancer, 1988, 42, 7-12.	5.1	83
94	Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6). International Journal of Cancer, 1988, 42, 787-791.	5.1	154
95	Biologically diverse molecular variants within a single HIV-1 isolate. Nature, 1988, 334, 444-447.	27.8	309
96	Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature, 1988, 334, 706-708.	27.8	158
97	Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science, 1988, 239, 68-71.	12.6	190
98	Relationship between HTLV-III Neutralizing Antibody and Clinical Status of Pediatric Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex Cases. Pediatric Research, 1987, 21, 547-550.	2.3	36
99	Human Retroviruses: HTLV-I, II, and III and Their Association with Leukemia and AIDS. Annals of the New York Academy of Sciences, 1987, 511, 350-369.	3.8	3
100	New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature, 1987, 328, 548-550.	27.8	101
101	Molecular Biology of Terminal Transferas. Critical Reviews in Biochemistry, 1986, 21, 27-52.	7.5	65
102	Hydrocortisone and some other hormones enhance the expression of HTLV-III. International Journal of Cancer, 1986, 37, 67-72.	5.1	127
103	STLV-I antibodies in feral populations of East African vervet monkeys (Cercopithecus aethiops). International Journal of Cancer, 1986, 38, 523-529.	5.1	54
104	Origins of human T-lymphotropic viruses. Nature, 1986, 320, 219-219.	27.8	13
105	The trans-activator gene of HTLV-III is essential for virus replication. Nature, 1986, 320, 367-371.	27.8	702
106	Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature, 1986, 320, 535-537.	27.8	260
107	First isolation of HTLV-III. Nature, 1986, 321, 119-119.	27.8	13
108	Reply to: Lack of evidence for involvement of known human retroviruses in multiple sclerosis. Nature, 1986, 322, 178-178.	27.8	6

#	Article	IF	CITATIONS
109	Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature, 1985, 313, 277-284.	27.8	2,554
110	HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature, 1985, 316, 72-74.	27.8	477
111	A molecular clone of HTLV-III with biological activity. Nature, 1985, 316, 262-265.	27.8	391
112	Human T-lymphotropic retroviruses. Nature, 1985, 317, 395-403.	27.8	683
113	Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature, 1985, 318, 154-160.	27.8	368
114	Seroepidemilogy of human T-lymphotropic retrovirus type I (HTLV-I) in residents of niigata prefecture, Japan. Comparative studies by indirect immunofluorescence microscopy and enzyme-linked immunosorbent assay. International Journal of Cancer, 1985, 35, 301-306.	5.1	17
115	Seroepidemiologic Studies Of Human T-cell leukemia/lymphoma virus type I in Jamaica. International Journal of Cancer, 1985, 36, 37-41.	5.1	77
116	Charles S. Mott Prize. Human T-cell leukemia (lymphotropic) retroviruses and their causative role in T-cell malignancies and acquired immune deficiency syndrome. Cancer, 1985, 55, 2317-2323.	4.1	20
117	Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virus. Cancer, 1985, 56, 495-499.	4.1	19
118	HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science, 1985, 227, 177-182.	12.6	955
119	Occurrence of HTLVâ€l antibodies in Danish patients with cutaneous Tâ€cell lymphoma. Scandinavian Journal of Haematology, 1985, 34, 455-462.	0.0	18
120	Retroviruses in Human T-Cell Malignancies. Cancer Investigation, 1984, 2, 467-478.	1.3	0
121	Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature, 1984, 310, 505-506.	27.8	115
122	Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature, 1984, 308, 464-467.	27.8	186
123	Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature, 1984, 312, 166-169.	27.8	360
124	Transformation of different phenotypic types of human bone marrow T-lymphocytes by htlv-1. International Journal of Cancer, 1984, 33, 13-17.	5.1	77
125	Location of human T-cell leukemia virus (HTLV) p19 antigen on virus-producing cells. International Journal of Cancer, 1984, 33, 161-165.	5.1	17
126	Natural antibodies to human T-cell leukemia/lymphoma virus in healthy venezuelan populations. International Journal of Cancer, 1984, 34, 501-506.	5.1	83

#	Article	IF	CITATIONS
127	Molecular cloning and analysis of a new variant of human T-cell leukemia virus (HTLV-Ib) from an African patient with adult T-cell leukemia-lymphoma. International Journal of Cancer, 1984, 34, 613-618.	5.1	64
128	Antibody to human T cell leukaemia virus type III in Australian homosexual men with lymphadenopathy. Medical Journal of Australia, 1984, 141, 274-276.	1.7	10
129	A survey of human leukaemias for sequences of a human retrovirus. Nature, 1983, 302, 626-628.	27.8	214
130	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma. Nature, 1983, 303, 253-256.	27.8	24
131	Nucleotide sequence of cloned cDNA of human c-myc oncogene. Nature, 1983, 303, 725-728.	27.8	324
132	Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. Nature, 1983, 304, 169-171.	27.8	171
133	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia–lymphoma: a retraction. Nature, 1983, 305, 340-340.	27.8	20
134	Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. Nature, 1983, 305, 733-736.	27.8	101
135	Persistentin vitro infection by human T-cell leukemia-lymphoma virus (HTLV) of normal human T-lymphocytes from blood relatives of patients with HTLV-associated mature T-cell neoplasms. International Journal of Cancer, 1983, 31, 171-180.	5.1	44
136	Infection and transformation of fresh human umbilical cord blood cells by multiple sources of human T-cell leukemia-lymphoma virus (HTLV). International Journal of Cancer, 1983, 31, 413-420.	5.1	124
137	Antibodies against human T-cell leukemia/lymphoma virus (HTLV) and expression of HTLV p19 antigen in relatives of a T-cell leukemia patient originating from Surinam. International Journal of Cancer, 1983, 32, 337-342.	5.1	25
138	Antibodies against three purified structural proteins of the human type-C retrovirus, HTLV, in Japanese adult T-cell leukemia patients, healthy family members, and unrelated normals. International Journal of Cancer, 1983, 32, 583-590.	5.1	15
139	Complete amino acid sequence of human T-cell leukemia virus structural protein p15. FEBS Letters, 1983, 162, 390-395.	2.8	75
140	Retroviruses in human leukemia. Hematological Oncology, 1983, 1, 193-204.	1.7	8
141	The human type-C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. International Journal of Cancer, 1982, 30, 257-264.	5.1	578
142	Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature, 1982, 295, 116-119.	27.8	514
143	onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature, 1982, 299, 61-63.	27.8	654
144	Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology, 1981, 112, 355-360.	2.4	324

#	Article	IF	CITATIONS
145	A human onc gene homologous to the transforming gene (v-sis) of simian sarcoma virus. Nature, 1981, 292, 31-35.	27.8	171
146	Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature, 1981, 294, 268-271.	27.8	758
147	The v-sis transforming gene of simian sarcoma virus is a new onc gene of primate origin. Nature, 1981, 294, 273-275.	27.8	51
148	Human T-cell growth factor: Parameters for production. Journal of Supramolecular Structure, 1980, 13, 229-241.	2.3	27
149	Placenta-bound immunoglobulins. Arthritis and Rheumatism, 1979, 22, 1308-1313.	6.7	7
150	Surface antibodies of human myelogenous leukaemia leukocytes reactive with specific type-C viral reverse transcriptases. Nature, 1978, 276, 230-236.	27.8	42
151	Antigenic characterization of a new gibbon ape leukemia virus isolate: Seroepidemiologic assessment of an outbreak of gibbon leukemia. International Journal of Cancer, 1978, 22, 715-720.	5.1	26
152	Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature, 1977, 270, 347-349.	27.8	2,063
153	Proviral sequences of baboon endogenous type C RNA virus in DNA of human leukaemic tissues. Nature, 1976, 262, 190-195.	27.8	64
154	Infective transmission and characterisation of a C-type virus released by cultured human myeloid leukaemia cells. Nature, 1975, 256, 551-555.	27.8	122
155	The evidence for involvement of type C RNA tumor viruses in human acute leukemia. Cancer, 1974, 34, 1398-1405.	4.1	16
156	Immunological Relationship of DNA Polymerase from Human Acute Leukaemia Cells and Primate and Mouse Leukaemia Virus Reverse Transcriptase. Nature, 1973, 244, 206-209.	27.8	145
157	Purification, Characterization, and Comparison of the DNA Polymerases from Two Primate RNA Tumor Viruses. Journal of Virology, 1973, 12, 431-439.	3.4	142
158	Chromatographic Analyses of Isoaccepting tRNAs from Avian Myeloblastosis Virus. Journal of Virology, 1973, 12, 449-457.	3.4	24
159	Selective Toxicity of Rifamycin Derivatives for Leukaemic Human Leucocytes. Nature: New Biology, 1972, 236, 166-171.	4.5	40
160	Reverse Transcriptase, RNA Tumour Virus Transformation and Derivatives of Rifamycin SV. Nature: New Biology, 1972, 236, 163-166.	4.5	75
161	RNA of RNA Tumour Viruses contains Poly A. Nature: New Biology, 1972, 236, 227-231.	4.5	195
162	Reverse Transcriptase Activity of Human Acute Leukaemic Cells: Purification of the Enzyme, Response to AMV 70S RNA, and Characterization of the DNA Product. Nature: New Biology, 1972, 240, 67-72.	4.5	173

#	Article	IF	CITATIONS
163	Asparaginyl-tRNA and Resistance of Murine Leukaemias to L-Asparaginase. Nature, 1970, 227, 1134-1136.	27.8	15
164	RNA Dependent DNA Polymerase of Human Acute Leukaemic Cells. Nature, 1970, 228, 927-929.	27.8	289
165	Transfer RNA's in human leukemia. Journal of Cellular Physiology, 1969, 74, 149-153.	4.1	39
166	Human Retroviruses in the Second Decade: Some Pathogenic Mechanisms and Approaches to Their Control. , 0, , 245-269.		0